Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib dose escalation study of JBH492 in relapsed/refractory CLL and NHL
jRCT2080225257Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of JBH492 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL), B-cell non-Hodgkin lymphoma (B-NHL) and 1 more, sponsored by Novartis. Primary endpoints: Safety and tolerability of JBH492 and Maximum tolerated dose and/or recommended dose of JBH492. Started Jun 2020; status: completed.
02
Drugs
JBH492
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)B-cell non-Hodgkin lymphoma (B-NHL)non-Hodgkin lymphoma, T-cell
Beyond the preview
Go deeper on jRCT2080225257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225257.